Expression of microRNA in tumor cells of endmetrioid carcinoma of endometrium
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-42-no-4.15522Keywords:
endometrioid endometrial carcinoma, microRNAs, miR-101, miR-125b, miR-142, miR-34aAbstract
Summary. Background: It is known that more than half of the genes encoding human proteins are regulated by various microRNAs (miRNAs, miR), the expression of which may be associated with various pathological conditions. At the same time, the question of assessing the relationship between the expression of particular miRNAs and the aggressive molecular subtype of endometrial cancer remains open. Aim of the study was to determine the relationship between the expression of miR-34a, miR-125b, miR-142 and miR-101 in endometrioid carcinomas of the endometrium (ECE) and the features of the disease course. Materials and Methods: The samples of surgical material of 51 patients with ECE (mean age 59.8 ± 7.1 years), I–III stage were investigated using morphological, immunohistochemical methods, real time polymerase chain reaction (PCR), cytofluorometry. Results: In endometrial tumors with high proliferation index (> Me), the expression of miR-34a, miR-142 and miR-125b significantly decreased (1.8, 2.7 and 1.5 times, respectively) compared with those in ECE with low proliferation index (< Me). The expression of all studied miRNAs was lower in G3 tumors and those that deeply invaded the myometrium compared to G2 carcinomas and tumors with an invasion of < 1/2 myometrium and significantly decreased in tumors of patients with low stage III compared with stage I–II. The high (> Me) microvessel density in ECE was associated with a significant decrease of miR-125b and miR-101 expression, and the presence of signs of epithelial-mesenchymal transition — with a decreased expression of miR-34a and miR-101. Conclusions: The study revealed a significant heterogeneity of expression of miR-34a, miR-125b, miR-142 and miR-101 in ECE, which is associated with changes in morphofunctional characteristics of endometrial carcinoma.
References
Fedorenko ZP, Gulak LO, Mikhailovich YU, et al. Cancer in Ukraine, 2017–2018. Morbidity, mortality, indicators of oncology service activity. Bull Nat Registry of Ukraine 2019; 20: 102 p. (in Ukrainian).
Soslow RA, Tornos C, Park KJ, et al. Endometrial carcinoma diagnosis: use of FIGO grading and genomic subcategories in clinical practice: recommendations of the international society of gynecological pathologists. Int J Gynecol Pathol 2019; 38: S64–73.
Rabban JT, Gilks CB, Malpica A, et al. Issues in the differential diagnosis of uterine low-grade endometrioid carcinoma, including mixed endometrial carcinomas: Recommendations from the International Society of Gynecological Pathologists. Int J Gynecol Pathol 2019; 38: S25–39.
Murali R, Davidson B, Fadare O, et al. High-grade endometrial carcinomas: morphologic and immunohistochemical features, diagnostic challenges and recommendations. Int J Gynecol Pathol 2019; 38: S40–63.
Iurchenko NP, Glushchenko NM, Buchynska LG. Assessment of DNA status and peculiarities of expression of cyclins D1 and transcription factor E2F1 in cells of epithelial endometrial tumors. Onkologiya 2019; 21: 230–7 (in Ukrainian).
Buchynska LG, Naleskina LА, Nesina IP. Мorphological characteristics and expression features of adhesion markers in cells of low differentiated endometrial carcinoma. Exp Oncol 2019; 41: 335–41.
Rapisuwon S, Vietsch EE, Wellstein A. Circulating biomarkers to monitor cancer progression and treatment. Comput Struct Biotechnol J 2016; 14: 211–22.
Veneziano D, Marceca GP, Di Bella S, et al. Investigating miRNA-lncRNA interactions: computational tools and resources. Methods Mol Biol 2019; 1970: 251–77.
Matsuyama H, Suzuki HI. Systems and synthetic microRNA biology: from biogenesis to disease pathogenesis. Int J Mol Sci 2020; 21: 132; doi: 10.3390/ijms21010132.
Jarroux J, Morillon A, Pinskaya M. History, discovery, and classification of lncRNAs. Adv Exp Med Biol 2017; 1008: 1–46.
Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010; 11: 597–610.
Liu B, Shyr Yu, Cai J, Liu Qi. Interplay between miRNAs and host genes and their role in cancer. Brief Funct Genomics 2019; 18: 255–66.
Sun L-L, Li W-D, Lei F-R, Li X-Q. The regulatory role of microRNAs in angiogenesis-related diseases. J Cell Mol Med 2018; 22: 4568–87.
Сhekhun VF. MicroRNAs a key factor in the globalization of tumor-host relationships. Exp Oncol 2019; 41: 188–94.
Kozomara A, Griffiths-Jones S. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucl Acids Res 2014; 42 (Database issue): D68–73.
Jayaraman M, Radhakrishnan R, Mathews CA, et al. Identification of novel diagnostic and prognostic miRNA signatures in endometrial cancer. Genes Cancer 2017; 8: 566–76.
Su Y, Wang J, Ma Z, et al. miR-142 suppresses endometrial cancer proliferation in vitro and in vivo by targeting cyclin Dl. DNA Cell Biol 2019; 38: 144–50.
Isobe T, Hisamori S, Hogan DJ, et al. miR-142 regulates the tumorigenicity of human breast cancer stem cells through the canonical WNT signaling pathway. Elife 2014; 3: e01977.
Shang C, Lu Y, Eng lR. MicroRNA-125b down-regulation mediates endometrial cancer invasion by targeting ERBB2. Med Sci Monit 2012; 18: 149–55.
Zuberi M, Khan I, Mir R, et al. Utility of serum mir-125b as a diagnosticand prognostic indicator and its alliance witha panel of tumor suppressor genes in epithelial ovarian cancer. PLoS ONE 1016; 11: e0153902. doi: 10.1371/journal.pone.0153902
Jiang F, Liu T, He Y, et al. MiR-125b promotes proliferation and migration of type II endometrial carcinoma cells through targeting TP53INP1 tumor suppressor in vitro and in vivo. BMC Cancer 2011; 11: 425.
Riquelme I, Tapia O, Leal P, et al. miR-101-2, miR-125b-2 and miR451 a act as potential tumor suppressors in gastric cancer through regulation of the PI3K/AKT/mTOR pathway. Cell Oncol 2016; 39: 23–33.
Agrawal S, Chaqour B. MicroRNA signature and function in retinal neovascularization. World J Biol Chem 2014; 5: 1–11.
Corrado G, Laquintana V, Loria R, et al. Endometrial cancer prognosis correlates with the expression of L1CAM and miR34a biomarkers. J Exp Clin Cancer Res 2018; 37: 139.
Wang, Z, Wang W, Huang K, et al. MicroRNA-34a inhibits cells proliferation and invasion by downregulating Notch l in endometrial cancer. Oncotarget 2017; 8: 111258–70.
Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nature Rev Drug Discovery 2017; 16: 203.
Dong P, Xiong Y, Yue J, et al. Exploring 1ncRNA-mediated regulatory networks in endometrial cancer cells and the tumor microenvironment: advances and challenges. Cancers 2019; 11: doi :10.3390/cancers11020234
Kurman RJ, Carcangiu M, Herrington CS, Young RH. WHO classification of tumours of the female reproductive organs (IARC WHO Classification of Tumours). 4th Edition Series: IARC Press 2014. 307 p.
Nesina IP, Iurchenko NP, Buchynska LG. Markers of the epithelial-mesenchymal transition in cells of endometrial carcinoma. Exp Oncol 2018; 40: 218–22.
Li W, Jia H, Wang J, et al. A CD44-specific peptide, RP-1, exhibits capacities of assisting diagnosis and predicting prognosis of gastric cancer. Oncotarget 2017; 8: 30063–76.
Guo F, Cogdell D, Hu L, et al. MiR-101 suppresses the epithelial-to-mesenchymal transition by targeting ZEB1 and ZEB2 in ovarian carcinoma. Oncol Rep 2014; 31: 2021–8.
Du R, Sun W, Xia L, et al. Hypoxia-induced down-regulation of microRNA-34a promotes EMT by targeting the Notch signaling pathway in tubular epithelial cells. PLoS One 2012; 7: e30771.
Kumar B, Yadav A, Lang J, et al. Dysregulation of microRNA-34a expression in head and neck squamous cell carcinoma promotes tumor growth and tumor angiogenesis. PLoS One 2012; 7: e37601.
Muramatsu F, Kidoya H, Naito H, et al. microRNA-125b
inhibits tube formation of blood vessels through translational suppression of VE-cadherin. Oncogene 2013; 32: 414–21.
Smits M, Mir SE, Nilsson RJ, et al. Down-regulation of miR-101 in endothelial cells promotes blood vessel formation through reduced repression of EZH2. PLoS One 2011; 6: e16282.
Liu Y, Li H, Zhao C, Jia H. MicroRNA-101 inhibits angiogenesis via COX-2 in endometrial carcinoma. Mol Cell Biochem 2018; 448: 61–9.
Misso G, Teresa M, Martino Di, De Rosa G. Mir-34: A new weapon against cancer? Mol Ther 2014; 3: e194; doi: 10.1038/mtna. 2014.47.
Kastenhuber ER, Lowe SW. Putting p53 in context. Cell 2017; 170: 1062–78.
Baniak N, Gilks CB, De Coteau J, Kinloch M. Diagnostic variation in p53 usage for endometrial carcinoma diagnosis: implications for molecular subtyping. Int J Gynecol Pathol 2019; 39: 514–21.
Buchynska LG, Iurchenko NP, Nesina IP, Glushchenko NM. Phenotypic features of endometrial cancer in patients with family history of cancer. Exp Oncol 2017; 39: 312–8.
Brieieva OV, Nesina IP, Iurchenko NP, Buchynska LG. Peculiarities of c-Myс protein expression in endometrial carcinomas with signs of aggressive disease. Oncologiya 2019; 21: 304–9 (in Ukrainian).
Buchynska LG, Brieieva OV, Iurchenko NP. Assessment of HER-2/neu, с-MYC and CCNE1 gene copy number variations and protein expression in endometrial carcinomas. Exp Оncol 2019; 41: 138–43.
Iurchenko NP, Glushchenko NM, Buchynska LG. Comprehensive analysis of intratumoral lymphocytes and FOXP3 expression in tumor cells of endometrial cancer. Exp Oncol 2014; 36: 353–8.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
